Filing Flows › Comparisons › IBO vs ONCO
Impact Biomedical vs Onconetix: IBO and ONCO compared
Impact Biomedical is the larger company: $21K of revenue in its latest quarter (Q3 2026) against $17K for Onconetix (Q2 2026). Impact Biomedical is growing faster (+17% against -84% a year earlier).
Where the money goes: IBO and ONCO
Impact Biomedical (IBO) · Q3 2026
Impact Biomedical, Q3 2026: revenue $21K (+17% year over year), net loss $644K, operating cash flow $11K. The chart follows the revenue to costs, profit and cash.
Onconetix (ONCO) · Q2 2026
Onconetix, Q2 2026: revenue $17K (-84% year over year), net loss $2.9M, operating cash flow −$1.9M. The chart follows the revenue to costs, profit and cash.
| Impact Biomedical (IBO) | Onconetix (ONCO) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q2 2026 |
| Revenue | $21K | $17K |
| Revenue growth, Y/Y | +17% | -84% |
| Operating margin | n/m | n/m |
| Net earnings | −$644K | −$2.9M |
| Operating cash flow | $11K | −$1.9M |
Questions
Which is bigger, Impact Biomedical or Onconetix?
Impact Biomedical is the larger company: $21K of revenue in its latest quarter (Q3 2026) against $17K for Onconetix (Q2 2026).
Is Impact Biomedical or Onconetix growing faster?
Impact Biomedical is growing faster (+17% against -84% a year earlier).
More: Impact Biomedical earnings · how Impact Biomedical makes money · Onconetix earnings · how Onconetix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 9, 2026; 10-Q filed Aug 13, 2026). Fiscal quarters can end on different dates. Not investment advice.